Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.22.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 168 $ 705 $ 379 $ 1,115
Cost of goods sold 113 211 153 318
Gross profit 55 494 226 797
Operating expenses:        
Research and development 3,331 2,374 5,842 4,236
General and administrative (related party of $61, $510, $250 and $903) 8,362 5,665 14,996 11,030
Total operating expenses 11,693 8,039 20,838 15,266
Operating loss (11,638) (7,545) (20,612) (14,469)
Other income (expense):        
Interest expense (related party of $202, $612, $810 and $1,226) (328) (615) (937) (1,229)
Interest income 35 27 71 31
Royalty income 5 2 5 2
Forgiveness of note payable and accrued interest - SBA loan 0 0 607 0
Other 6 0 6 0
Total other income (expense) (282) (586) (248) (1,196)
Consolidated net loss (11,920) (8,131) (20,860) (15,665)
Net loss attributable to noncontrolling interest 0 2 1 3
Net loss attributable to iBio, Inc. (11,920) (8,129) (20,859) (15,662)
Preferred stock dividends (22) (65) (88) (131)
Net loss attributable to iBio, Inc. stockholders (11,942) (8,194) (20,947) (15,793)
Comprehensive loss:        
Consolidated net loss (11,920) (8,131) (20,860) (15,665)
Other comprehensive loss - unrealized loss on debt securities (27) (13) (28) (20)
Comprehensive loss $ (11,947) $ (8,144) $ (20,888) $ (15,685)
Loss per common share attributable to iBio, Inc. stockholders - basic $ (0.05) $ (0.04) $ (0.10) $ (0.09)
Weighted-average common shares outstanding - basic and diluted 217,990 188,087 217,933 175,264